Johnson & Johnson (NYSE:JNJ) is Foyston Gordon & Payne Inc’s 2nd Largest Position

Foyston Gordon & Payne Inc cut its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 12.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 117,417 shares of the company’s stock after selling 16,928 shares during the quarter. Johnson & Johnson accounts for 6.7% of Foyston Gordon & Payne Inc’s portfolio, making the stock its 2nd largest position. Foyston Gordon & Payne Inc’s holdings in Johnson & Johnson were worth $23,106,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. RE Dickinson Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after purchasing an additional 98 shares during the period. Advanced Research Investment Solutions LLC increased its holdings in shares of Johnson & Johnson by 200.0% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after purchasing an additional 120 shares during the period. Morton Brown Family Wealth LLC increased its holdings in shares of Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares during the period. Professional Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after purchasing an additional 68 shares during the period. Finally, Goodman Advisory Group LLC acquired a new position in Johnson & Johnson in the second quarter worth approximately $39,000. 68.59% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.5 %

JNJ opened at $176.82 on Wednesday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $462.29 billion, a price-to-earnings ratio of 24.63, a P/E/G ratio of 3.49 and a beta of 0.57. The business has a 50 day moving average of $168.35 and a 200-day moving average of $171.28.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the prior year, the business earned $2.60 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson declared that its board has initiated a stock repurchase program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a $1.13 dividend. The ex-dividend date is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.56%. Johnson & Johnson’s dividend payout ratio is 62.95%.

Insider Activity

In related news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider William Hait sold 15,000 shares of the firm’s stock in a transaction on Monday, October 24th. The stock was sold at an average price of $171.55, for a total value of $2,573,250.00. Following the completion of the transaction, the insider now directly owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The disclosure for this sale can be found here. Over the last three months, insiders sold 135,723 shares of company stock valued at $23,192,574. 0.35% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on JNJ shares. Morgan Stanley dropped their price objective on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 19th. Citigroup dropped their price objective on Johnson & Johnson from $201.00 to $198.00 in a report on Wednesday, October 5th. Sanford C. Bernstein dropped their price objective on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Raymond James dropped their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Finally, Bank of America dropped their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Seven research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $181.33.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.